ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas

Gu, Qiang; Li, Lang; Yao, Jiahao; Dong, Fa-yan; Gan, Yifan; Zhou, Shuhuai; Wang, Xinyu; Wang, Xue-feng*哈尔滨医科大学
Frontiers in Oncology2023-3-7DOI: 10.3389/fonc.2023.1120103
7阅读
引用收藏
分享

摘要

IntroductionThe most important chemotherapy treatment for glioma patients is temozolomide. However, the development of drug resistance severely restricts the use of temozolomide. Therefore, elucidating the mechanism of temozolomide resistance, enhancing temozolomide sensitivity, and extending patient survival are urgent tasks for researchers. MethodsTemozolomide resistance hub differential genes were identified using differential analysis and protein interaction analysis from the GEO datasets (GSE100736 and GSE113510). These genes were further studied in glioma patients treated with temozolomide in the TCGA and CGGA databases. Patients from the mRNAseq_325 dataset (CGGA) were considered as the training set to construct a risk model for predicting glioma sensitivity to temozolomide, while patients from the mRNAseq_693 dataset (CGGA) and TCGA-GBM dataset were considered as the validation set to evaluate the performance of models. PCR and western blot were performed to determine the difference in expression of the feature gene DACH1 between glioma cells and temozolomide-resistant glioma cells. The alterations in the sensitivity of tumor cells to temozolomide were also observed after DACH1 was silenced. The patients were then divided into two groups based on the expression of DACH1, and the differences in patient survival rates, molecular pathway activation, and level of immune infiltration were compared. ResultsBased on four signature genes (AHR, DACH1, MGMT, and YAP1), a risk model for predicting glioma sensitivity to temozolomide was constructed, and the results of timeROC in both the training and validation sets showed that the model had good predictive performance. The expression of the signature gene DACH1 was significantly downregulated in temozolomide-resistant cells, according to the results of the PCR and western blot experiments. The sensitivity of tumor cells to temozolomide was significantly reduced after DACH1 was silenced. DACH1 probably regulates temozolomide resistance in glioblastoma through the transcriptional dysregulation in cancer and ECM. DiscussionThis study constructs a risk model that can predict glioma susceptibility to temozolomide and validates the function of the feature gene DACH1, which provides a promising target for the research of temozolomide resistance.

学科与关键词

关键词
gliomatemozolomidedrug-resistancerisk modelmachine learning
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2023-03-07
卷期
第 13 卷
页码
1120103
DOI
10.3389/fonc.2023.1120103
成果收录
SCIE

作者

  • G

    Gu, Qiang (第一作者)

    harbin med univ

  • L

    Li, Lang

    harbin med univ

查看全部 8 位作者收起作者
  • Y

    Yao, Jiahao

    harbin med univ

  • D

    Dong, Fa-yan

    harbin med univ

  • G

    Gan, Yifan

    harbin med univ

  • Z

    Zhou, Shuhuai

    harbin med univ

  • W

    Wang, Xinyu

    harbin med univ

  • W

    Wang, Xue-feng (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417